Personalized Oral Therapies Will Transform Global Healthcare Markets

AnalystConsensusTarget

Not Invested

Consensus Narrative from 9 Analysts

Published

09 Sep 25

AnalystConsensusTarget's Fair Value

JP¥1,794.44

45.1% undervalued

09 Sep

JP¥986.00

-24.0%

-0.4%

-24.0%

-0.4%

Edit anytime before Sep 9 8:18 PM. Then post Updates to your followers.

Author's Valuation

JP¥1.8k

45.1% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

JP¥1.79k

45.1% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

7.88%

Pharma revenue growth rate

0.60%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

4.72%

Calculation

JP¥3.13b

Earnings '28

60.52x

PE Ratio '28

JP¥189.59b

Market Cap '28

JP¥189.59b

Market Cap '28

92.30m

No. shares '28

JP¥2.05k

Share Price '28

JP¥2.05k Share Price '28

Discounted to 2025 @ 4.72% p.a.

JP¥1.79k

Fair Value '25